Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
What This Means
Featuring Akari Therapeutics
February 11, 2026
Abizer Gaslightwala, CEO of Akari Therapeutics, discusses Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors.
What This Means
Featuring Decoy Therapeutics
February 4, 2026
Peter Marschel, Chief Business Officer of Decoy, discusses how the Company’s “design-for-manufacturing” approach supports the rapid transition of peptide-conjugate therapeutics from laboratory development to commercial-scale production and is designed to enable a distributed global manufacturing network capable of responding to emerging viral threats. The platform will be validated using Decoy’s intranasal pan-coronavirus fusion inhibitor, which is funded under the same Gates Foundation grant.
What This Means
Featuring Ernexa Therapeutics
February 3, 2026
Sanjeev Luther, President & CEO of Ernexa, highlighs how regulatory alignment from the FDA on Ernexa’s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026.
CEO Connect
Featuring SENTI Bio
January 14, 2026
Timothy Lu, MD, PhD, CEO of Senti, discusses its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML.
What This Means
Featuring Autonomix
December 23, 2025
Brad Hauser, CEO of Autonomix, outlines two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.
What This Means
Featuring Akari Therapeutics
December 18, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics highlights the recently announced new preclinical data that demonstrates the therapeutic potential of Akari’s lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer.
What This Means
Featuring American Resources
December 8, 2025
Mark Jensen, Executive Chairman of American Resources and CEO of ReElement Technologies, and Jacob Clayton, CEO of SAGINT Inc., discuss the strategic collaboration between the companies to implement blockchain-based tokenization for global critical mineral traceability and transparency.
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
Past Events
Closing Bell
CEO Connect